194 related articles for article (PubMed ID: 13679631)
1. The Fas/Fas ligand system and cancer: immune privilege and apoptosis.
Abrahams VM; Kamsteeg M; Mor G
Mol Biotechnol; 2003 Sep; 25(1):19-30. PubMed ID: 13679631
[TBL] [Abstract][Full Text] [Related]
2. Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams VM; Straszewski SL; Kamsteeg M; Hanczaruk B; Schwartz PE; Rutherford TJ; Mor G
Cancer Res; 2003 Sep; 63(17):5573-81. PubMed ID: 14500397
[TBL] [Abstract][Full Text] [Related]
3. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
[TBL] [Abstract][Full Text] [Related]
4. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis.
Meng Y; Kang S; So J; Reierstad S; Fishman DA
Gynecol Oncol; 2005 Feb; 96(2):462-9. PubMed ID: 15661236
[TBL] [Abstract][Full Text] [Related]
5. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
6. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
7. Fas and Fas ligand interactions in malignant disease.
Owen-Schaub L; Chan H; Cusack JC; Roth J; Hill LL
Int J Oncol; 2000 Jul; 17(1):5-12. PubMed ID: 10853011
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.
Perabo FG; Kamp S; Schmidt D; Lindner H; Steiner G; Mattes RH; Wirger A; Pegelow K; Albers P; Kohn EC; von Ruecker A; Mueller SC
Br J Cancer; 2001 May; 84(10):1330-8. PubMed ID: 11355943
[TBL] [Abstract][Full Text] [Related]
9. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
11. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart PM; Griffith TS; Usui N; Pepose J; Yu X; Ferguson TA
J Clin Invest; 1997 Feb; 99(3):396-402. PubMed ID: 9022072
[TBL] [Abstract][Full Text] [Related]
12. [CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors].
Ungefroren H; Voss M; Henne-Bruns D; Kremer B; Kalthoff H
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):63-7. PubMed ID: 14518214
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
14. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
15. Fas-mediated apoptosis in tumor formation and defense.
Hug H
Biol Chem; 1997 Dec; 378(12):1405-12. PubMed ID: 9461339
[TBL] [Abstract][Full Text] [Related]
16. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
19. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
20. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
